In a corporate update, Relmada Therapeutics said it would like to thank outgoing chief medical officer, Dr. Cedric O’Gorman, for his contribution in the optimization of the clinical development strategy for the REL 1017 studies 302 and 304. “We also welcome Dr. Andrew Cutler as Senior Clinical Development Advisor, who will help Relmada through the completion of the REL-1017 Phase 3 program and the NDA/approval process,” the company said.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RLMD:
- Rising High: Exclusive talk with REIT Healing Realty Trust
- Rising High: Exclusive talk with biotech company Tryp Therapeutics
- Rising High: Exclusive talk with cannabis REIT NewLake Capital
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Rising High: Exclusive talk with cannabis market research firm BDSA
